Home › Funds › BlackRock › iShares Health Innovation Active ETF
Fund family: BlackRock · Filed by BlackRock ETF Trust (CIK 1761055) · SEC series S000069260
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 595 with, 13 against, 8 abstentions (not counted as with management); 3 items carried no recommendation. Shareholder proposals: 1 FOR, 12 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as BlackRock’s manager page (1,606,521 ballot items across 392 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | BlackRock | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 97.3% | 553 | 93.6% | 1,355,861 |
| Backed environmental and social shareholder proposals at US companies | n/a | 2 | 5.5% | 6,306 |
Each ballot item this fund voted is set against the votes of the other BlackRock funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most BlackRock funds on 18 items (3.1% of the 585 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most BlackRock funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| ROIVANT SCIENCES LTD. | 2025-09-10 | To cast a non-binding, advisory vote to approve the compensation of our named executive officers. | For | AGAINST — 32 of 35 BlackRock funds | For | Approved, 60.9% support |
| BIO-TECHNE CORP | 2025-10-30 | Approve, on an advisory basis, the compensation of our executive officers. | Against | FOR — 35 of 42 BlackRock funds | Against | Approved, 72.1% support |
| HOLOGIC, INC. | 2026-02-05 | A proposal to approve, on an advisory (non-binding) basis, the compensation that may be paid or become payable to the named executive officers of the Company in connection with the transactions contemplated by the merger agreement, including consummation of the merger. | For | AGAINST — 50 of 64 BlackRock funds | For | — |
| INCYTE CORPORATION | 2026-06-08 | Approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers. | For | AGAINST — 54 of 73 BlackRock funds | For | Approved, 83.9% support |
| EXACT SCIENCES CORPORATION | 2026-02-20 | Proposal to approve, on an advisory (nonbinding) basis, the compensation that may be paid or become payable to Exact Sciences Corporation's named executive officers that is based on or otherwise related to the Merger Agreement and the transactions contemplated by the Merger Agreement (the "Compensat | For | AGAINST — 31 of 40 BlackRock funds | For | — |
| WUXI BIOLOGICS (CAYMAN) INC. | 2026-06-10 | Approve Deloitte Touche Tohmatsu as Auditors and Authorize the Board of Directors or Any Duly Authorized Board Committee to Fix Their Remuneration | Against | FOR — 13 of 15 BlackRock funds | Against | — |
| WUXI BIOLOGICS (CAYMAN) INC. | 2026-06-10 | Elect Ge Li as Director | Against | FOR — 13 of 15 BlackRock funds | Against | — |
| INCYTE CORPORATION | 2026-06-08 | Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: Jean-Jacques Bienaimé | For | AGAINST — 44 of 60 BlackRock funds | For | — |
| WAVE LIFE SCIENCES LTD. | 2025-08-05 | To authorize the Board of Directors to allot and issue Ordinary Shares of Wave Life Sciences Ltd. | Against | FOR — 14 of 17 BlackRock funds | Against | Approved, 78.2% support |
| SUMMIT THERAPEUTICS INC. | 2026-06-10 | Approval of an amendment to the Summit Therapeutics Inc. 2020 Stock Incentive Plan to Increase the Number of Shares of Common Stock. | For | AGAINST — 14 of 18 BlackRock funds | For | Passed (calculated), 95.8% support |
| SUMMIT THERAPEUTICS INC. | 2026-06-10 | DIRECTOR: Kenneth A. Clark | For | ABSTAIN — 14 of 18 BlackRock funds | For | — |
| AVIDITY BIOSCIENCES, INC. | 2026-02-26 | To approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to our named executive officers in connection with the transactions contemplated by the Merger Agreement and the Separation Agreement. | For | AGAINST — 23 of 34 BlackRock funds | For | Approved, 82.4% support |
| PROTAGONIST THERAPEUTICS, INC. | 2026-06-17 | DIRECTOR: L.T. Williams, MD, PhD | Abstain | FOR — 19 of 28 BlackRock funds | Against | — |
| BRIGHT MINDS BIOSCIENCES INC. | 2026-03-31 | DIRECTOR: David Weiner | Abstain | FOR — 8 of 10 BlackRock funds | Against | — |
| BRIGHT MINDS BIOSCIENCES INC. | 2026-03-31 | DIRECTOR: Jan Pedersen | Abstain | FOR — 8 of 10 BlackRock funds | Against | — |
| BRIGHT MINDS BIOSCIENCES INC. | 2026-03-31 | DIRECTOR: Jeremy Fryzuk | Abstain | FOR — 8 of 10 BlackRock funds | Against | — |
| MODERNA, INC. | 2026-05-06 | To approve, on a non-binding, advisory basis, the compensation of our named executive officers. | Against | FOR — 33 of 59 BlackRock funds | Against | Approved, 65.1% support |
| MERUS N.V. | 2025-12-09 | Non-binding advisory proposal to approve certain compensation arrangements | For | AGAINST — 12 of 19 BlackRock funds | For | Passed (calculated), 55.9% support |
Download all 18 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 71.4% of this fund’s 616 such votes could be given a sector; the other 176 (28.6%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 384 | 12 | 3.1% |
| Industrials | 56 | 1 | 1.8% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 392 | 0 |
| Say-on-Pay | 54 | 0 |
| Audit-related | 51 | 0 |
| Corporate Governance | 50 | 8 |
| Capital Structure | 27 | 0 |
| Compensation | 25 | 0 |
| Shareholder Rights and Defenses | 9 | 3 |
| Extraordinary Transactions | 8 | 0 |
| Other Social Issues | 6 | 2 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| MERCK & CO., INC. | May 26, 2026 | $696,586 | 18 | 3 |
| JOHNSON & JOHNSON | April 23, 2026 | $679,382 | 15 | 1 |
| AMGEN INC. | May 19, 2026 | $607,951 | 15 | 1 |
| EDWARDS LIFESCIENCES CORPORATION | May 7, 2026 | $600,459 | 12 | 0 |
| CHARLES RIVER LABORATORIES INTL., INC. | May 5, 2026 | $587,390 | 15 | 0 |
| BIOGEN INC. | June 9, 2026 | $486,943 | 12 | 0 |
| WATERS CORPORATION | May 21, 2026 | $460,771 | 13 | 0 |
| INTUITIVE SURGICAL, INC. | April 30, 2026 | $436,437 | 13 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 26, 2026 | MERCK & CO., INC. | Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposal | Against | For |
| May 26, 2026 | MERCK & CO., INC. | Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposal | Against | For |
| April 23, 2026 | JOHNSON & JOHNSON | Independent Board Chair Shareholder proposal | Against | For |
| May 19, 2026 | AMGEN INC. | Stockholder proposal to require an independent board chairman. Shareholder proposal | Against | For |
| April 30, 2026 | GILEAD SCIENCES, INC. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 30, 2026 | GILEAD SCIENCES, INC. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| May 13, 2026 | VERTEX PHARMACEUTICALS INCORPORATED | Shareholder Proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposal | Against | For |
| May 12, 2026 | IDEXX LABORATORIES, INC. | Shareholder Proposal to Give Shareholders the Ability to Call for a Special Shareholder Meeting (Proposal Six). Shareholder proposal | Against | For |
| April 23, 2026 | IQVIA HOLDINGS INC. | If properly presented, a stockholder proposal concerning separate Chairman and Chief Executive Officer roles. Shareholder proposal | Against | For |
| April 21, 2026 | BIO-RAD LABORATORIES, INC. | Stockholder proposal regarding dual class capital structure. Shareholder proposal | For | Against |
| April 23, 2026 | PFIZER INC. | Adopt an Independent Chair Policy Shareholder proposal | Against | For |
622 ballot items at 59 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, iShares Health Innovation Active ETF voted at 59 shareholder meetings of 57 companies, on 622 ballot items in all. Where management made a recommendation, the fund followed it on 96.6% of the items and voted against it 13 times. Its most frequent area of disagreement was corporate governance (8 of its votes against management). It voted on 13 shareholder proposals. It voted FOR the board's own proposals more often than BlackRock's funds as a whole (97.3% against 93.6%). It voted differently from most BlackRock funds on 18 items.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of BlackRock’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.